Immatics Pipeline Progress
Immatics Reports Q2 Revenue Gains, Advances SUPRAME and Other Oncology Programs Towards Milestones
Key Points
SUPRAME progression data are accruing more slowly than originally modeled, prompting Immatics to proceed directly to a streamlined final analysis for the primary PFS endpoint while preserving statistical power for OS.
Updated Phase 1b data for anZu-cel (IMA203) show activity in gynecologic cancers with a 63% overall response rate and 50% confirmed response rate.
IMA402 PRAME bispecific plus IMA401 MAGEA4/8 bispecific combination in squamous non-small cell lung cancer is enrolling, with first data expected in 2027 at the ESMO Congress.
A Moderna collaboration milestone related to dosing of its mRNA-4200 candidate was triggered in July 2026, signaling ongoing external partnerships and potential value realization beyond Immatics’ own programs.
Immatics’ second-quarter 2026 R&D expenditure rose to about $71.1 million from $51.4 million year-over-year, contributing to a higher operating loss and underscoring the cash-intensive nature of advancing multiple PRAME-targeted programs.
Immatics reported Q2 2026 collaboration revenue of $10.4 million, nearly double the $5.4 million from a year earlier, according to Grafa. The biotech narrowed its net loss to $71.2 million and said it still holds about $448.2 million in cash, giving it a runway into 2028.
Despite the revenue beat, the company's earnings per share came in at a loss of $0.46, just slightly better than the consensus estimate of $0.48, TipRanks noted. Shares were little changed in early trading, hovering near $9.25, as investors focus on upcoming clinical data rather than near-term profits.
SUPRAME Phase 3 Trial Heads Toward 2027 BLA Filing
Immatics' flagship SUPRAME trial is enrolling patients across North America and Europe, and the company expects to finish randomizations by year-end, TipRanks reported. Progression events are building more slowly than originally expected. Because of that, Immatics will skip an interim look and go straight to a final analysis of the primary endpoint — progression-free survival, or PFS, meaning how long patients live without their cancer getting worse.
Topline PFS data are expected in the first half of 2027. If results are positive, Immatics plans to submit a biologics license application, or BLA, to the FDA in 2027. The company said the streamlined approach protects the trial's ability to detect a meaningful benefit for overall survival as well, according to Grafa.
Anzu-cel Shows 56% Confirmed Response Rate in Melanoma
Updated data on anzu-cel, also called IMA203, show a 56% confirmed response rate in patients with metastatic melanoma — a form of skin cancer that has spread. The drug is a T-cell therapy, meaning it uses a patient's own immune cells to attack cancer. Activity has also been seen in gynecologic cancers, where the overall response rate reached 63%, TipRanks reported.
Immatics is also advancing IMA203CD8, a next-generation version of anzu-cel. The company targets PRAME, a protein found on the surface of many cancer types. Management described the response data as durable, meaning patients kept responding over time rather than quickly relapsing.
R&D Costs Surge 38% as Pipeline Expands Beyond PRAME
Research and development spending jumped to $71.1 million in Q2 2026, up from $51.4 million a year earlier — a 38% increase, according to Market Screener. That rise pushed the operating loss higher even as revenue grew. The company attributed the higher costs to running multiple clinical programs at once.
Beyond anzu-cel, Immatics is enrolling patients in a study combining two bispecific antibodies — IMA402 and IMA401 — in squamous non-small cell lung cancer. First data from that combination are expected at the ESMO Congress in 2027. Separately, a milestone payment from Moderna was triggered in July 2026 after dosing of its mRNA-4200 candidate, signaling that partnerships are also delivering value, Scanx Trade noted.
Cash Runway Intact But Financing Needs Loom Ahead
With $448.2 million in cash and financial assets, Immatics says it can fund operations into 2028. That gives the company time to reach its biggest catalyst: topline SUPRAME data in H1 2027. But running multiple Phase 1 and Phase 3 programs at the same time is expensive, and the 38% jump in R&D spending shows costs are rising fast.
Analysts had expected a loss of $0.48 per share; Immatics posted a loss of $0.46, a small beat, Scanx Trade reported. Revenue of $10.4 million also topped some estimates. Still, the company remains years away from product revenue, and any delay in SUPRAME could force it back to capital markets sooner than planned.
Sentiment
Mostly PositivePublishers
10
Articles
23
Reach
33
